OncoMatch/Clinical Trials/NCT06167694
Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
Is NCT06167694 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies HRS-8080; Dalpiciclib Isethionate Tablets for unresectable or metastatic breast cancer.
Treatment: HRS-8080; Dalpiciclib Isethionate Tablets — This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion. Participants entering the study will receive HRS-8080 combined with Dalpiciclib Isethionate Tablets therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: endocrine therapy — advanced/metastatic
Dose-exploration stage: advanced stage has received at least 1 line of endocrine therapy progression in the past
Cannot have received: nitrosourea
Received nitrosourea or mitomycin within 6 weeks before the first dose in this study
Cannot have received: mitomycin
Received nitrosourea or mitomycin within 6 weeks before the first dose in this study
Cannot have received: cytotoxic chemotherapy
cytotoxic drugs ... within 4 weeks before the first medication
Cannot have received: immunotherapy
immunotherapy ... within 4 weeks before the first medication
Cannot have received: targeted therapy
targeted therapy ... within 4 weeks before the first medication
Cannot have received: anti-tumor traditional Chinese medicine
anti-tumor traditional Chinese medicine ... within 4 weeks before the first medication
Cannot have received: other clinical investigational drugs
other clinical investigational drugs within 4 weeks before the first medication
Cannot have received: endocrine therapy
He received endocrine therapy ... within 2 weeks before the first dose
Cannot have received: palliative radiotherapy
He received ... palliative radiotherapy within 2 weeks before the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify